Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Consolidated Net Income (2016 - 2025)

Sangamo Therapeutics has reported Consolidated Net Income over the past 16 years, most recently at -$37.4 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 59.94% year-over-year to -$37.4 million; the TTM value through Dec 2025 reached -$122.9 million, down 25.52%, while the annual FY2025 figure was -$122.9 million, 25.52% down from the prior year.
  • Consolidated Net Income for Q4 2025 was -$37.4 million at Sangamo Therapeutics, down from -$34.9 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $21.1 million in Q1 2023 and troughed at -$114.5 million in Q2 2023.
  • A 5-year average of -$42.5 million and a median of -$43.6 million in 2022 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: tumbled 3063.26% in 2021 and later skyrocketed 148.01% in 2023.
  • Year by year, Consolidated Net Income stood at -$37.5 million in 2021, then tumbled by 38.61% to -$52.0 million in 2022, then decreased by 16.01% to -$60.3 million in 2023, then surged by 61.2% to -$23.4 million in 2024, then tumbled by 59.94% to -$37.4 million in 2025.
  • Business Quant data shows Consolidated Net Income for SGMO at -$37.4 million in Q4 2025, -$34.9 million in Q3 2025, and -$20.0 million in Q2 2025.